Financial Results - BioRestorative Therapies, Inc. announced its financial results for Q3 2024, with a focus on business updates and performance metrics[2]. - The financial press release is intended to provide summary information in the context of the company's SEC filings and public announcements[3]. - The company has not filed the information in the press releases as part of its SEC obligations, indicating it is not subject to certain liabilities[4]. - The CFO, Robert Kristal, signed the report on November 13, 2024, indicating the company's compliance with SEC requirements[10]. Clinical Trials - The company is presenting additional preliminary data from the ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the ORS symposium[6]. - The conference call discussing Q3 results will also include a review of the BRTX-100 presentation[6]. - The company is committed to transparency regarding its clinical trials and financial performance[7]. - The presentation materials from the symposium may be used in future communications with investors and stakeholders[6]. Research and Development - The company continues to focus on research and development as part of its growth strategy[6]. - The press releases and presentation materials are not incorporated by reference into any registration statement unless specifically identified[7].
BioRestorative Therapies(BRTX) - 2024 Q3 - Quarterly Results